Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Lenalidomide, and Dexamethasone in POEMS Syndrome
NCT02921893Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ixazomib in POEMS syndrome (POEMS) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Rate of normalization of VEGF at 3 months. Started Oct 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
POEMS syndrome (POEMS)
Beyond the preview
Go deeper on NCT02921893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921893.